0000914190-19-000460.txt : 20191206
0000914190-19-000460.hdr.sgml : 20191206
20191206165056
ACCESSION NUMBER: 0000914190-19-000460
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191204
FILED AS OF DATE: 20191206
DATE AS OF CHANGE: 20191206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WIENS HAROLD J
CENTRAL INDEX KEY: 0001197788
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17272
FILM NUMBER: 191273622
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIO-TECHNE Corp
CENTRAL INDEX KEY: 0000842023
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 411427402
STATE OF INCORPORATION: MN
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 614 MCKINLEY PL N E
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
BUSINESS PHONE: 6123798854
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
FORMER COMPANY:
FORMER CONFORMED NAME: TECHNE CORP /MN/
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-12-04
0000842023
BIO-TECHNE Corp
TECH
0001197788
WIENS HAROLD J
614 MCKINLEY PLACE NE
MINNEAPOLIS
MN
55413
1
0
0
0
Common Stock
2019-12-04
4
M
0
2000
87.83
A
7221
D
Common Stock
2019-12-04
4
S
0
485
216.4747
D
6736
D
Common Stock
2019-12-04
4
S
0
514
217.2852
D
6222
D
Common Stock
2019-12-04
4
S
0
921
218.7545
D
5301
D
Common Stock
2019-12-04
4
S
0
80
219.3139
D
5221
D
Stock Option (right to buy)
87.83
2019-12-04
4
M
0
2000
0
D
2014-05-15
2024-05-15
Common Stock
2000
0
D
Stock Option (right to buy)
91.78
2014-10-30
2024-10-30
Common Stock
4000
4000
D
Stock Option (right to buy)
87.34
2016-10-29
2025-10-28
Common Stock
4260
4260
D
Stock Option (right to buy)
101.19
2017-10-26
2026-10-26
Common Stock
3985
3985
D
Stock Option (right to buy)
125.05
2018-10-25
2027-10-26
Common Stock
3125
3125
D
Stock Option (right to buy)
179.84
2019-10-24
2028-10-25
Common Stock
1898
1898
D
Stock Option (right to buy)
201.64
2029-10-24
Common Stock
2011
2011
D
The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.00 to $216.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.21 to $217.54, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.28 to $218.96, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.31 to $219.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Brenda S. Furlow as Attorney-in-Fact for Harold J. Wiens pursuant to Power of Attorney previously filed.
2019-12-06